Key facts
- RenalGuard’s last known valuation is $48.5M (Mar 2017).
- It has raised $21.5M; the latest was Later Stage VC in Jan 2025.
- Notable investors include Abiomed, Coridea, Exigent Capital Group, Genesis Capital Advisors (New York), Kidron.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for RenalGuard
- ·The full record, as it builds
Funding rounds
No funding rounds for RenalGuard are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RenalGuard
Developer of medical devices designed to treat cardiac and vascular-related ailments. The company's devices rapidly removes contrast dyes that are known to be toxic to the kidneys to minimize the risk of under-hydration while maintaining the high urine flows recommended for the prevention of cervical intraepithelial neoplasm, enabling clinical practitioners to treat their patients suffering from acute renal failure in an improved way.
- Sector
- Healthcare
- HQ
- Milford, MA, United States
- Founded
- 2014
- Employees
- 36
- Website
- cardiorenalsystems.com/
- Ownership
- Privately Held (backing)
RenalGuard doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RenalGuard shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RenalGuard in its N-PORT filings yet. We sweep new filings monthly.